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Increased and sustained expression of p-Akt in HCC827 cells with 
the acquired resistance to gefitinib
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Ryoo, Bae-Yeol; Lee, Jin Kyung; Yang, Sung Hyun; Kim, Cheol Hyeon 
Korea Cancer Center Hospital, Seoul, Korea
Geﬁtinib, a speciﬁc inhibitor of epidermal growth factor receptor 
tyrosine kinase (EGFR-TK), has shown promising activity in lung 
cancer. However, tumor cells eventually acquire the resistance limiting 
duration of efﬁcacy. To characterize lung cancer cells with the acquired 
resistance to geﬁtinib, a resistant subline HCC827/GR was established 
by repeated exposure to the drug for more than 6 months. Compared 
with parent HCC827 cells having delE746-A750 mutation, HCC827/
GR cells were 5676.8-fold more resistant to geﬁtinib and showed the 
cross-resistance against erlotinib and cetuximab. However, the resis-
tance to other chemotherapeutic drugs such as CL-387,785, ZD6474, 
cisplatin, etoposide, gemcitabine and paclitaxel, developed to a lesser 
degree suggesting that they would have more favorable response. 
Several factors related with the sensitivity to geﬁtinib were evaluated. 
The secondary mutation of T790M was not detected by sequencing 
and EGFR gene copy number by FISH was not changed. In addition, 
the epithelial-to-mesenchymal transition was not found. However, 
the expression of p-Akt was markedly increased and not reduced by 
treatment with geﬁtinib. The redundant pathways to activate Akt other 
than EGFR might develop and exert an important role in the acquired 
resistance to geﬁtinib. 
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Background: Almost all NSCLC that attained disease control on 
EGFR TKI would eventually become resistant. About 50% of cases 
are associated with secondary mutation in EGFR (e.g. T790M at exon 
20). Previously, Cetuximab alone (an EGFR monoclonal antibody), 
has been shown to induce growth inhibition of a geﬁtinib-resistant 
NSCLC line harboring T790M. Here, we attempt to overcome geﬁtinib 
resistance by combined targeting of geﬁtinib with HER-1 (EGFR) 
and HER-2 with monoclonal antibodies cetuximab and trastuzumab, 
respectively. We hypothesize that combination of monoclonal antibod-
ies with geﬁtinib may elicit synergistic antitumor activity in geﬁtinib-
resistant NSCLC cell line.
Methods: NSCLC Cell lines: NCI-H1650 (DelE746A750) is geﬁtinib-
sensitive, and NCI-H1975 (L858R, T790M) is geﬁtinib-resistant. Cells 
were treated with respective drug alone or in combination for 72h. 
Growth inhibition was evaluated by MTT assay. Effect of combination 
treatment on EGF-induced phosphorylation of Akt and MAPK was 
determined by Western blotting. 
Results: Percentage of cell kill by combined treatment of cetuximab 
and geﬁtinib on NCI-H1975 (geﬁtinib-resistant) was superior to 
geﬁtinib alone, and the combination was able to restore to level similar 
to geﬁtinib alone on the sensitive cell line (NCI-H1650). However, ad-
dition of cetuximab was only mildly synergistic on NCI-H1975 (~30% 
enhanced cell kill over the theoretical additive cell kill of the two 
agents alone). We demonstrated that the geﬁtinib/cetuximab combina-
tion, but not geﬁtinib alone, was able to down-regulate EGF-induced 
phosphorylation of Akt and MAPK in NCI-H1975 in a dose-dependent 
manner (Figure 1). Addition of trastuzumab could further increase cell 
kill of the geﬁtinib/cetuximab combination on NCI-H1975 cell lines. 
Keeping concentration of cetuximab at 0.5ug/ml and geﬁtinib at 10uM 
we found the synergism (over three agents alone) with addition of 
trastuzumab being most pronounced at lower dose (Table 1).
Conclusion: T790M associated EGFR TKI resistance is potentially 
reversible. Addition of cetuximab with or without trastuzumab restore 
cell kill in resistant cell line. 
Trastuzumab conc Theoretical Cell Kill Experimental Cell Kill
Increase in %  
of Cell Kill
0.5 13.9 27.1 95%
0.1 7.2 26.2 263%
0.01 9.9 25.6 158%
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Putative biomarker genes for pemetrexed theatment in small 
and non-small cell lung cancer cell lines, detected by microarray 
analysis
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Background: The multitargeted antifolate (pemetrexed disodium; Al-
imta) is indicated for the treatment of patients with locally advanced or 
metastatic NSCLC after prior chemotherapy as a single-agent, and with 
malignant pleural mesothelioma in combination with platinum. We 
have investigated putative biomarker genes of pemetrexed sensitivity 
with SCLC and NSCLC cell lines. 
Materials and Methods: Nine different lung cancer cell lines were 
used: squamous (H157), adenocarcinoma (A549, H1648, H2122, and 
H1975), bronchioalveolar carcinoma (H358), and extensive stage small 
cell carcinoma (H69, H526, and H748). These cells were grown at 
37˚C in humid atmosphere containing 5% CO
2
 in RPMI-1640 medium 
supplemented with 10% fetal bovine serum. All cell counts were made 
with a hematocytometer using trypan blue exclusion to distinguish 
between live and dead cells. NSCLC cells were seeded at 1-2*104 /ml, 
and SCLC cells were seeded at 1-2*105 /ml in 96-well plates (100μl/
well). They were incubated at 37˚C for 16-24 hours prior to pemetrexed 
treatment. Drug or control medium (100μl/well) were added at the 
incubated concentration, and proliferation was assessed for all cell lines 
over a 6-day time course. MTT 50μl was added to each well, and plates 
